#Canada #Montreal #Thryv Therapeutics #SGK1 inhibitors #Long QT Syndrome

Thryv Therapeutics to Present Key Clinical Results

Thryv Therapeutics Inc., a pioneering biotechnology company based in Montreal, is set to share its latest clinical findings regarding novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors aimed at treating cardiovascular diseases. The company will participate in two esteemed investor conferences in New York City, where it will discuss significant recent advancements in their clinical programs and clinical trial outcomes.

Clinical Highlights from HRS 2025

On April 27, 2025, during the Heart Rhythm Society (HRS) Annual Meeting, Thryv Therapeutics revealed crucial data from Part 2 of the Wave I study, focusing on Long QT Syndrome (LQTS). This study included adult participants with genetically confirmed Long QT Syndrome Types 2 or 3, who were administered oral doses of LQT-1213 over a two-and-a-half-day period. The findings indicated that the drug was well-tolerated and produced promising results. Significant reductions in the QTcF interval were observed among participants in the higher dose group, with a notable reduction in QTcF AUC demonstrated by a mean decrease of 11 milliseconds (p=0.028). Additionally, the peak-to-trough analysis revealed an impressive 53 milliseconds reduction in QTc (p<0.0001), underscoring LQT-1213's potential as a game-changing therapeutic option for patients suffering from this serious condition.

Upcoming Investor Conferences

RBC Capital Markets Global Healthcare Conference 2025

• - Dates: May 20–21, 2025
• - Location: InterContinental New York Barclay, New York, NY

At this prominent event, Thryv will participate in a fireside chat scheduled for May 21 at 9:30 AM EST. Furthermore, there will be opportunities for investors to engage in one-on-one discussions regarding the future of Thryv's clinical programs and details about their Series B financing efforts.

Jefferies Global Healthcare Conference 2025

• - Dates: June 3–5, 2025
• - Location: New York Marriott Marquis, New York, NY

During this conference, Thryv Therapeutics will offer one-on-one meetings to delve deeper into the company's strategic direction and upcoming initiatives.

Overview of the Wave I Study

The Wave I study is designed to evaluate the safety and efficacy of LQT-1213 in patients affected by both congenital and acquired forms of Long QT Syndrome. In Part 1 of this study, which was presented at the American College of Cardiology's Annual Scientific Session in March 2024, initial safety data were collected. Part 2 involved a placebo-controlled, multi-dose safety assessment focusing on patients with congenital Long QT Syndrome Types 2 or 3, with detailed findings presented at the 2025 HRS Annual Meeting.

Understanding SGK1 Inhibitors

Thryv's research centers on a series of selective SGK1 inhibitors, targeting the mechanisms that contribute to electrical and structural remodelling in cardiac health. Abnormal activation of SGK1 is associated with conditions like Long QT Syndrome and can adversely impact heart function. By inhibiting SGK1, Thryv aims to offer a transformative approach to treatment, addressing underlying issues that lead to disorders such as heart failure and atrial fibrillation.

What is Long QT Syndrome?

Long QT Syndrome is characterized by a delay in the heart's electrical repolarization, leading to an extended QT interval on an ECG, which can result in potentially fatal arrhythmias. This condition can be congenital or acquired, with a notable prevalence of about 1 in 2,000 individuals globally.

About Thryv Therapeutics

As a forward-thinking company, Thryv Therapeutics is committed to developing advanced treatment options for Long QT Syndrome, heart failure, and atrial fibrillation through precise medicine strategies. The firm's ongoing research and anticipated clinical transitions are expected to innovate the landscape of cardiovascular treatment. For further information, visit Thryv's website.